§ Head-to-Head Comparison

Tirzepatide vs Retatrutide.

Clinical research comparison of Tirzepatide vs Retatrutide: SURMOUNT-1 Phase 3 vs Phase 2 trial data, mechanisms, and half-life.

Advanced

Editor's Note

IMPORTANT: These weight-loss figures come from SEPARATE trials of different durations (SURMOUNT-1: 72 weeks vs Jastreboff Phase 2: 48 weeks) and are not directly comparable. Furthermore, retatrutide data is Phase 2 (338 participants, investigational, not FDA-approved), while tirzepatide data is from Phase 3 registration trials for an approved drug. Phase 2 results should not be treated as equivalent-strength evidence to Phase 3.

Quick Verdict

Tirzepatide achieved ~20.9% weight loss in Phase 3 trials (72wk). Retatrutide Phase 2 data showed ~24.2% (48wk) via tri-agonist mechanisms. Tirzepatide is established; Retatrutide is highly experimental.

Side-by-Side Analysis

DimensionTirzepatideRetatrutide
MechanismDual receptor agonism at GLP-1 and GIP receptors for synergistic appetite suppression, improved insulin sensitivity, and enhanced metabolic function.Multi-receptor activation for appetite suppression, fat oxidation, energy expenditure.
Primary BenefitsWeight loss, body recomposition, glycemic controlSuperior body recomposition, massive fat loss, metabolic health
Typical Dose2500–2500mcg2000–2000mcg
RouteSubQSubQ
Frequency1x/wk1x/wk
Half-Life120 hours144 hours
FDA StatusApprovedApproved
Evidence Gradevery-strongstrong
Key Studies20+ indexed20+ indexed
Weight Loss (Trial)
~20.9%
SURMOUNT-1 · 72 weeks · n=2,539
Phase 3 · PMID 35658024
Treatment-regimen estimand; efficacy estimand reports ~22.5% at 15mg
~24.2%
Jastreboff et al. Phase 2 · 48 weeks · n=338
Phase 2 · PMID 37351564
Phase 2 investigational data — not FDA-approved; Phase 3 TRIUMPH trials ongoing
Lowest Price$69.99 / 5mg via Amino Club$69.99 / 10mg via Amino Club

Which one should you choose?

**Data Context & Limitations:** The clinical figures cited below are drawn from separate clinical trials—the SURMOUNT-1 trial (72 weeks) and Jastreboff et al. Phase 2 trial (48 weeks). There are no direct, head-to-head trials comparing these specific compounds. Weight loss percentages are therefore not perfectly comparable. Furthermore, while tirzepatide figures stem from large Phase 3 registration trials supporting FDA approval, retatrutide data is currently limited to Phase 2 investigational data (338 participants) and is not FDA-approved. **The Verdict:** Retatrutide represents the next investigational frontier in metabolic therapies. By adding glucagon receptor agonism to the GLP-1 and GIP activity seen in tirzepatide, retatrutide achieved a striking ~24.2% average weight loss in 48 weeks during Phase 2 trials—a higher figure than the ~20.9% (treatment-regimen estimand) seen with tirzepatide in its separate 72-week trial. Crucially, tirzepatide is a thoroughly evaluated medication backed by massive Phase 3 data (SURMOUNT trials). Retatrutide remains an experimental, unapproved compound currently undergoing Phase 3 trials (TRIUMPH). While its initial Phase 2 efficacy ceiling appears higher, its full safety profile and long-term tolerability remain unestablished compared to tirzepatide. For researchers, retatrutide offers a novel mechanism to study tri-agonist pharmacology, whereas tirzepatide is a highly validated dual-agonist. *This information is provided for research and educational purposes only and does not constitute medical or prescribing advice.*

Who Should Choose Tirzepatide?

Choose Tirzepatide if you:

  • Want a fully FDA-approved, well-characterized agent
  • Need comorbid T2DM glycemic control alongside weight loss
  • Prefer extensive Phase 3 and real-world safety data
  • Are a first-time GLP-1 researcher needing a reliable benchmark

Who Should Choose Retatrutide?

Choose Retatrutide if you:

  • Are researching extreme obesity (BMI >40) where dual agonism has plateaued
  • Want to study glucagon receptor-mediated thermogenesis and lipolysis
  • Are comfortable with Phase 2 data and research-phase compounds
  • Need to target MASLD (metabolic-associated steatotic liver disease)

Can you stack Tirzepatide + Retatrutide?

Do NOT stack Tirzepatide and Retatrutide — both share GLP-1 and GIP receptors. Concurrent use creates additive receptor saturation risk with compounded nausea and hypoglycemia. Use only one GLP-1-class agent at a time.

Vendor Pricing

· Affiliate links · Prices verified 2026

Tirzepatide

2 vendors
Amino Club Best Value
5mg vial · $14.00/mg
$69.99Buy
Limitless Life
5mg vial · $16.00/mg
$80.00Buy
Full vendor comparison for Tirzepatide

Retatrutide

1 vendor
Amino ClubEditor's Pick Best Value
10mg vial · $7.00/mg
$69.99Buy
Full vendor comparison for Retatrutide

Affiliate disclosure: PeptiDex may earn a commission from purchases via vendor links at no extra cost to you. See our methodology.

Frequently Asked Questions

Phase 2 data shows Retatrutide achieving ~24% weight loss vs Tirzepatide's ~21% (Phase 3). But Tirzepatide is FDA-approved with extensive safety data. Retatrutide is still in Phase 3 trials with no approval timeline confirmed.

Related Comparisons

Weight Loss

Semaglutide vs Tirzepatide

Read comparison

Progression

Semaglutide vs Retatrutide

Read comparison

GLP-1

Tirzepatide vs Semaglutide

Read comparison

Deep Dive Profiles

Tirzepatide Research Profile Retatrutide Research Profile

Research Tools

PK Plasma Curves

Visualize Tirzepatide & Retatrutide plasma concentration over time

Reconstitution Calculator

Calculate precise dilution volumes and concentrations

Research Use Only — Not Medical Advice

This comparison is provided for educational and research purposes only. It does not constitute medical, prescribing, or treatment advice. Clinical data cited here is sourced from published peer-reviewed trials and FDA labels. Consult a qualified healthcare professional before making any decisions about medications or research compounds. PeptiDex is an informational resource and does not sell pharmaceutical products.